Jagsonpal Pharmaceuticals Ltd
Updates on Acquisition of Aequitas Healthcare Private Limited
M&A
▲ Positive Development
LOW RISK
📅 Filed on BSE: 08 Jul 2026, 04:49 PM IST · BSE ID: ebff9e7f-41bc-4a9f-922d-44903c53fb40
View Original BSE Filing (PDF)
💡
In Simple Terms
Jagsonpal Pharma has acquired 77.21% of Aequitas Healthcare, making it a subsidiary company.
🤖 AI Summary
- Jagsonpal Pharmaceuticals Ltd. completed acquisition of 77.21% equity stake in Aequitas Healthcare Private Limited.
- The completed stake is against a previously proposed acquisition of 85% equity in Aequitas Healthcare.
- This makes Aequitas Healthcare Private Limited a subsidiary of Jagsonpal Pharmaceuticals Ltd.
- Previous filings indicated a total acquisition cost of INR 20.8 Crore for 85% stake.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Equity stake acquired in Aequitas Healthcare Private Limited
77.21%
Previously proposed equity stake for acquisition
85%
🏢 How This Affects the Company
The acquisition expands Jagsonpal Pharmaceuticals' presence by entering the hospital segment, diversifying its business operations.
This transaction will consolidate Aequitas Healthcare's financials with Jagsonpal Pharmaceuticals, affecting its balance sheet and P&L.
Jagsonpal Pharmaceuticals will integrate Aequitas Healthcare's operations, potentially expanding its workforce and service capabilities within the healthcare sector.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this disclosure.
👤
Who Is Affected
Shareholders of Jagsonpal Pharmaceuticals Ltd. will see Aequitas Healthcare Private Limited's operations and financials consolidated into the parent company.
🔍
Management Signal
Management is actively pursuing strategic acquisitions to expand business operations and enter new healthcare segments.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q1 FY27 financial results — check consolidated financials including Aequitas Healthcare.
Future updates on the remaining proposed 7.79% equity stake in Aequitas Healthcare.
Management commentary on Aequitas Healthcare's integration and performance.
LOW RISK
This filing represents a transaction completion, reducing execution risk of the announced acquisition.
💡 Investor Takeaway
Jagsonpal Pharmaceuticals Ltd. completed the acquisition of 77.21% equity stake in Aequitas Healthcare Private Limited. This follows earlier intimations to acquire 85% stake for INR 20.8 Crore, positioning Aequitas as a subsidiary.
⚖️ Strengths & Concerns
✅ Positives
- Completed 77.21% equity stake acquisition in Aequitas Healthcare Private Limited, establishing it as a subsidiary.
- Expansion into the hospital segment, diversifying Jagsonpal Pharmaceuticals' business portfolio as previously announced.
⚠️ Concerns
- The completed acquisition percentage of 77.21% is less than the previously proposed 85% equity stake.
- The filing does not detail the financial terms or exact amount paid for the 77.21% stake.
📅 Company Track Record
Jagsonpal Pharmaceuticals Ltd. had previously announced on June 29, 2026, its intention to acquire 85% of Aequitas Healthcare Private Limited for INR 20.8 Crore to enter the hospital segment. On July 7, 2026, the company informed of completing 69.77% stake acquisition, and this filing updates that to 77.21%.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What percentage of Aequitas Healthcare has Jagsonpal Pharmaceuticals acquired?
Jagsonpal Pharmaceuticals Ltd. has completed the acquisition of 77.21% equity stake in Aequitas Healthcare Private Limited.
Was the completed acquisition percentage in Aequitas Healthcare as previously proposed?
The company completed the acquisition of 77.21% equity stake, against the previously proposed acquisition of 85% equity stake.
What is the status of Aequitas Healthcare Private Limited after this acquisition?
Following the acquisition of 77.21% equity stake, Aequitas Healthcare Private Limited is now a subsidiary of Jagsonpal Pharmaceuticals Ltd.
What was the total proposed cost for the Aequitas Healthcare acquisition?
Previous filings indicated Jagsonpal Pharmaceuticals intended to acquire 85% of Aequitas Healthcare for INR 20.8 Crore.
Questions based on this BSE filing only. For information purposes.